Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00718692 · ClinicalTrials.gov registry record · Phase 2
Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)
A Phase 2 study, sponsored by Symphogen A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT00718692 is a Phase 2 study that has completed, run by Symphogen A/S. The registered enrollment target is 61 participants.
The verdict
NCT00718692, a Phase 2 study, has completed, sponsored by Symphogen A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
This trial is designed as a multi-centre, single-dose, exploratory dose-finding, open label trial evaluating the safety and efficacy of Sym001 in 4-9 consecutive cohorts. Subjects will receive a single IV dose of Sym001.
Interventions
- DRUG Sym001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00718692
The ClinicalTrials.gov registry entry for NCT00718692 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Symphogen A/S, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sym001 is the first listed.
NCT00718692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00718692 about?
NCT00718692 is a clinical study titled "Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)". This trial is designed as a multi-centre, single-dose, exploratory dose-finding, open label trial evaluating the safety and efficacy of Sym001 in 4-9 consecutive cohorts. Subjects will receive a single IV dose of Sym001.
What is the current status of trial NCT00718692?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2008-07. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00718692?
The interventions under investigation include: Sym001 (DRUG).
Who is sponsoring clinical trial NCT00718692?
This trial is sponsored by Symphogen A/S, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.